Absence of p53 Overexpression and Favorable Response to Cisplatin‐based Neoadjuvant Chemotherapy in Urothelial Carcinomas

It has been controversial whether cancer cells harboring loss or inactivation of the tumor suppressor p53 are resistant or sensitive to DNA‐damaging agents including cisplatin and doxorubicin. Overexpression of mdm2 oncoprotein, a negative regulator of p53, is assumed to be an alternative to p53 dys...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Jpn J Cancer Res
Autors principals: Kakehi, Yoshiyuki, Özdemir, Enver, Habuchi, Tomonori, Yamabe, Hirohiko, Hashimura, Takayuki, Katsura, Yoshitaka, Yoshida, Osamu
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 1998
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5921759/
https://ncbi.nlm.nih.gov/pubmed/9548450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.1998.tb00551.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars